Henry Schein AI Stock Analysis
Want to see HSIC full AI Analyst Report?
Henry Schein (HSIC) AI Stock Analysis
Henry Schein
(NASDAQ:HSIC)
HSIC scores as moderately attractive, led by strong earnings-call momentum (raised EPS guidance, margin expansion, share gains, and confidence in cash flow) and generally steady operating performance. The score is held back by increased balance-sheet leverage and weakening recent free-cash-flow trend, while technical indicators are currently bearish and valuation (P/E ~23.8) does not look meaningfully discounted without dividend support.
Henry Schein Key Performance Indicators (KPIs)
Operating Income by SegmentShows how profitable each major business line is after operating costs, highlighting which segments drive earnings, where margins are under pressure, and how efficiently management converts sales into profit.
A 2024 reporting recast shuffled profits out of legacy Healthcare/Tech lines into new Global Distribution, Speciality Products and Global Technology segments, while large negative “Adjustments” and a growing Corporate drag reflect restructuring, remeasurement and other one‑offs that depress GAAP operating income. Management’s guidance raise and $200M+ value‑creation plan suggest the underlying global segments are expanding margins and driving real profitability, but investors should watch the pace of adjustment reversals and Corporate G&A to see how much of the improvement converts to GAAP results.
Henry Schein (HSIC) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $9.39B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.28M
- Price to Earnings (P/E)
- 22.9
- Beta (1Y)
- 0.32
- Revenue Growth
- 6.15%
- EPS Growth
- 15.68%
- Country
- US
- Employees
- 25,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
Henry Schein Business Overview & Revenue Model
Company Description
Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, go...
How the Company Makes Money
Henry Schein makes money primarily by selling and distributing healthcare products and practice-related solutions to professional customers. A large portion of revenue comes from ongoing, repeat purchases of consumable supplies used in routine patien...
Henry Schein Earnings Call Summary
The call was strongly positive. Highlights significantly outweighed the challenges, with 8.6% U.S. dental merchandise growth driven primarily by volume and share gains, 19.1% underlying adjusted EPS growth, margin expansion, strong cash flow, ongoing value-creation benefits, raised EPS guidance, and continued technology and home-solutions growth. The company acknowledged pressure in discretionary dental procedures, lower point-of-care diagnostic and vaccine demand, a Brazil headwind, restructuring costs, and the nonrecurring nature of the tariff refund benefit, but management said these issues do not materially alter current growth expectations.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Henry Schein’s 2026 total sales growth expectations remain unchanged at 4.5 to 5.5 percent over 2025, while 2026 non GAAP diluted EPS attributable to Henry Schein, Inc. is now expected to be $5.50 to $5.56, compared to prior guidance of $5.29 to $5.39, and 2026 adjusted EBITDA is expected to grow in the high single digits versus 2025 adjusted EBITDA of $1.1 billion; the guidance assumes no significant additional tariff refunds or remeasurement gains for the remainder of 2026, foreign currency exchange rates will remain generally consistent with current levels, and an estimated non GAAP effective tax rate of approximately 24%. The company continues to expect more than $200 million of operating income improvement, including a $125 million run rate by the end of 2026, and operating cash flow to exceed net income for the full year; management expects double digit EPS growth for the full year of 2026 and expressed confidence in achieving double-digit earnings growth in 2027, with targeted and limited growth investments in the fourth quarter contributing to growth in 2027, expects fourth quarter technology sales growth to be in line with the first half of this year, expects U. S. Dental equipment growth to continue in the fourth quarter, and expects an early 2027 US flu season to support better medical growth in Q4.
Henry Schein Financial Statement Overview
Summary
Income statement trends are steady (TTM revenue up vs prior year; stable operating profitability), but net margins are relatively thin (~3%) versus earlier years. The main drag is balance-sheet leverage rising materially (debt ~1.21x equity), reducing flexibility, while cash flow remains positive but has weakened recently (TTM free cash flow down vs prior period and only moderate debt coverage).
Income Statement
72PositiveBalance Sheet
55NeutralCash Flow
61Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.73B | 13.18B | 12.67B | 12.34B | 12.65B | 12.40B |
| Gross Profit | 4.20B | 3.84B | 3.77B | 3.65B | 3.65B | 3.67B |
| EBITDA | 1.09B | 1.01B | 912.00M | 851.00M | 977.00M | 1.07B |
| Net Income | 421.00M | 398.00M | 390.00M | 416.00M | 538.00M | 623.91M |
Balance Sheet | ||||||
| Total Assets | 11.51B | 11.21B | 10.22B | 10.57B | 8.61B | 8.48B |
| Cash, Cash Equivalents and Short-Term Investments | 184.00M | 156.00M | 122.00M | 171.00M | 117.00M | 118.00M |
| Total Debt | 3.89B | 3.69B | 2.87B | 2.74B | 1.50B | 1.22B |
| Total Liabilities | 6.78B | 6.42B | 5.38B | 5.42B | 3.94B | 3.81B |
| Stockholders Equity | 3.16B | 3.25B | 3.39B | 3.65B | 3.45B | 3.42B |
Cash Flow | ||||||
| Free Cash Flow | 529.00M | 573.00M | 661.00M | 313.00M | 506.00M | 630.57M |
| Operating Cash Flow | 687.00M | 712.00M | 848.00M | 500.00M | 602.00M | 709.58M |
| Investing Cash Flow | -318.00M | -477.00M | -430.00M | -1.14B | -276.00M | -677.22M |
| Financing Cash Flow | -346.00M | -111.00M | -510.00M | 701.00M | -315.00M | -332.96M |
Henry Schein Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HSIC, the sentiment is Negative. The current price of 84.96 is below the 20-day moving average (MA) of 85.87, below the 50-day MA of 85.81, and above the 200-day MA of 81.57, indicating a neutral trend. The MACD of 0.26 indicates Negative momentum. The RSI at 47.00 is Neutral, neither overbought nor oversold. The STOCH value of 49.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HSIC.
Henry Schein Risk Analysis
Henry Schein disclosed 29 risk factors in its most recent earnings report. Henry Schein reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksHenry Schein Peers Comparison
Overall Rating
CAH73Outperform
HSIC64Neutral
MCK64Neutral
YI40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | $65.61B | 36.58 | -62.56% | 0.72% | 10.00% | 16.74% | |
| 64Neutral | $9.39B | 22.88 | 13.13% | ― | 6.15% | 15.68% | |
| 64Neutral | $127.58B | 28.38 | -161.18% | 0.31% | 8.19% | 21.01% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 40Underperform | $24.95M | -1.57 | 23.64% | ― | -23.90% | -45.45% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HSIC | Henry Schein | 84.96 | 14.36 | 20.34% | |
| CAH | Cardinal Health | 283.85 | 78.27 | 38.07% | |
| MCK | McKesson Corporation | 1105.04 | 255.91 | 30.14% | |
| AHG | Akso Health Group Sponsored ADR | 1.33 | -0.20 | -13.07% | |
| YI | 111, Inc. | 2.84 | -0.96 | -25.26% |
Henry Schein Corporate Events
Henry Schein Announces CFO Transition and Leadership Enhancements
PositiveHenry Schein, Inc. is a products, services, and technology platforms company focused on healthcare customers, supplying office-based dental and medical practitioners, dental laboratories, and institutional and government clinics with more than 300,00...
Henry Schein Expands and Extends Revolving Credit Facility
PositiveOn September 21, 2026, Henry Schein amended and restated its revolving credit agreement, expanding the aggregate commitments from $1 billion to $1.25 billion and extending the facility’s termination date to September 19, 2031. The revised facility, a...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026
